SWI Initiates Coverage on VG Life Sciences Inc.

StockWatchIndex Initiates Coverage on VG Life Sciences Inc.
VG Life Sciences Inc. (VGLS:OTCQB)


Los Angeles, CA, April 6,2015. StockWatchindex announced today that it has initiated coverage of VG Life Sciences, Inc. (VGLS:OTCQB). VGLS is a drug discovery and development company researching inflammatory disease applications for the treatment of different cancers and other inflammatory diseases based on two promising and proprietary technologies developed by VGLS:

Targeted Peptide Technology (TPT)
Metabolic Disruption Technology (MDT) 

VGLS Research and Development programs are based on technology developed by VGLS' lead scientist Dr. Karen Newell Rogers, while working at the University of Colorado, the University of Vermont and Texas A&M University. VGLS holds the exclusive rights to this technology. VGLS collaborates with a multitude of scientists and clinicians at universities throughout the country, including Stanford University, Harvard University and Scott & White Healthcare Center, where it tests the use of its TPT inflammatory disease applications. VGLS has also contracted with the University of Utah to conduct a comprehensive Theiler Virus mouse model, using its patented VG1177 compound.

VG Life Sciences, Inc.
In cooperation with Doctors at Scott White Healthcare in Temple, Texas and the Cancer Therapy and Research Center at the University of Texas, San Antonio, VGLS has completed a Phase I Physician's IND trial, for patients with solid cancerous tumors, utilizing an MDT compound, called "Hydroxychloroquine" in combination with an existing cancer drug called "Sorafenib", which is marketed as Nexavar® by Bayer AG and Onyx Pharmaceuticals.
VGLS Major Milestones
  • Completed Phase I cancer trials at the University of Texas for the VGLS
    combination drug treatment
  • Continued animal safety studies for the patented VG1177 compound
  • Owns a large body of patents and patent applications for the use of the VGLS
    Metabolic Disruption Technology (MDT)
  • Holds the Use Patent for a VGLS combination drug co-developed with 
    Bayer AG and Onyx Pharmaceuticals
  • Patent Office in DC indicates issuance of composition patent for VG1177
  • VGLS Scientific Adviser Dr.Richard Tobin, PhD publishes data on VG1177
    for impact on neural damage treatment
  • Initiated and completed prior year independent company financial audits
  • Filed SEC Form 10 and became a fully reporting company on OTCQB
  • Up-listed the company off the Pink-Sheets to the OTC Marketplace
Targeted Peptide Technology (TPT)
VG Life Sciences holds the exclusive worldwide license to to over 45 domestic and foreign patents or patents pending (1 issued US patent, 9 pending US applications and 10 pending foreign applications). The Targeted Peptide Technology (TPT) rights are in part covered by at least 20 U.S. and foreign patents and/or patent applications under which VG Life Sciences, Inc. has exclusive license.

Metabolic Disruption Technology (MDT)
VG Life Sciences Inc. holds exclusive licenses to over 26 U.S. and foreign patents and/or patent applications underlying the use of Metabolic Disruption Technology (MDT) compounds for the treatment of cancers. VGLS currently conducts an ongoing FDA Phase I clinical trial for drug-resistant carcinomas at the Cancer Treatment and Research Center in San Antonio, Texas, and is nearing the IND stage for several other indications. 
VGLS is in the process of completing its Phase I Physician's IND study utilizing MDT as a combination therapy. Currently, the company has one pre-clinical and one clinical-stage candidate. VGLS's pre-clinical product candidate is a TPT therapy for HIV/AIDS, using its computational designed peptide known as VG1177. Currently, the company is devoting most of its resources to develop VG1177.
Please visit our new service We would appreciate if you could pass our newsletter on to your friends and colleagues and naturally, we always appreciate your feedback and comments.

About SWI
SWI is a leading edge PR, Information Marketing and Research firm with a highly frequented web site, its "Rise Above The Noise" newsletter and SWI Research site These services provide readers with information and research on new and promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analyst reports and opinions from credible Wall Street firms that we respect and frequently sample. The weekly SWI QuickPicks  Ratings Report keeps you informed about newly SWI initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by these companies and do not necessarily hold positions in any of these stocks.  You can conveniently follow the live links for each of these stocks on for more detail.  SWI's periodical "Portfolio Performance Report" frequently reports about the performance of the stocks that we have purchased and may be trading in the SWI portfolio. Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site  
Google +
Good luck and please pass this newsletter on to a friend
to continue building our community.

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise) of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrants any results from use of the information. We have contracted with some of the companies we present on SWI or in the SWI Newsletter as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options, which may be considered a potential conflict of interest. SWI has been compensated by a third party for this report. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or in any of its other publications. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice.

Copyright © 2015 DynamicMarketConcepts, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp